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Background: Previous trials examining the use of bupropion as a smoking cessation therapy in post-acute myocardial infarction (AMI) patients 
have been inconclusive. These findings may be explained, in part, by adherence to study medication.
Methods: We used data from a placebo-controlled, randomized trial of bupropion in smokers (N=392) hospitalized with AMI to determine the 
effect of treatment adherence on abstinence. Adherence was assessed by self-report throughout the 9-week treatment period. Patients were 
classified as adherent if they reported taking 2 pills/day at each follow-up. Abstinence was assessed by 7-day biochemically-validated self-report at 
9 weeks and 6 and 12 months. Patients lost to follow-up were considered to be non-adherent and to have returned to smoking.
Results: Patients were predominantly male (83.3%), and the mean age was 53.8 yrs (SD 10.4). Patients who were adherent to treatment 
(bupropion or placebo) reported greater abstinence than those who were not. In patients who were adherent, the prevalence of smoking abstinence 
at all follow-ups was similar in the two treatment groups (Table). Conversely, among those who were not adherent, randomization to bupropion 
resulted in a substantial increase in abstinence.
Conclusions: Adherence to study medication, regardless of assigned treatment, is associated with substantial increases in abstinence. Post-AMI 
patients with lower levels of motivation may derive greater benefit from the use of bupropion for smoking cessation. 
Prevalence of biochemically-validated smoking abstinence by treatment and 9-week adherence.
Adherent (%) Non-Adherent (%)
Difference (Adherent- Non-Adherent) (95% 
CI)
9 Weeks (N=385) Bupropion 74.2 41.8 32.4 (18.7, 46.2)
Placebo 65.2 29.6 35.5 (22.4, 48.7)
Difference (Bupropion-Placebo) (95% 
CI)
9.1 (-5.4, 23.5) 12.2 (-0.1, 24.5) --
6 Months (N=380) Bupropion 53.0 39.5 13.5 (-1.4, 28.4)
Placebo 48.3 25.5 22.8 (9.6, 36.1)
Difference (Bupropion- Placebo) (95% 
CI)
4.7 (-11.2, 20.6) 14.0 (1.9, 26.1) --
12 Months (N=377) Bupropion 52.3 35.6 16.7 (1.8, 31.6)
Placebo 48.9 22.6 26.2 (13.1, 39.4)
Difference (Bupropion- Placebo) (95% 
CI)
3.4 (-12.6), 19.5) 13.0 (1.2, 24.7) --
